A Phase 2 interventional study of verteporfin and verteporfin in Choroidal Neovascularization and Macular Degeneration, sponsored by QLT Inc.. Completed at 26 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-06-02.
Sponsored by QLT Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 16th largest by enrollment, is one of 7 that started in 2007, is one of 10 in phase 2, and was the 10th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
QLT Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
QLT Inc. has 1 study filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy [within 2 hours]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter
Drug: verteporfin · Drug: ranibizumab · Drug: dexamethasone
Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter
Drug: verteporfin · Drug: ranibizumab · Drug: dexamethasone
Reduced-fluence Visudyne followed by Lucentis double therapy \[within 2 hours\] administered on Day 0, and then as required every 2 months thereafter
Drug: verteporfin · Drug: ranibizumab
Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
Drug: ranibizumab
Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
Also known as: Visudyne, photodynamic therapy
Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
Also known as: Visudyne, photodynamic therapy
0.5 mg intravitreal injection
Also known as: Lucentis
0.5 mg intravitreal injection
Mean Number of Retreatments (Day 0 Excluded)
Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.
Time frame: Month 1 to Month 12
Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)
Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100
Time frame: Baseline to Month 12
Mean Number of Retreatments (Day 0 Excluded)
Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.
Time frame: Month 1 to Month 24
Mean Change From Baseline in Study Eye Best-Corrected VA Score
Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100
Time frame: Baseline to Month 24
Percentage of Subjects With >=15 Letters of Visual Acuity Gained From Baseline
Time frame: Baseline to Month 12, Baseline to Month 24
Percentage of Subjects With >=0 Letter Gain of Visual Acuity From Baseline
Time frame: Baseline to Month 12, Baseline to Month 24
Percentage of Subjects With >=15 Letters of Visual Acuity Lost From Baseline
Time frame: Baseline to Month 12, Baseline to Month 24
Mean Change From Baseline in Central Retinal Thickness
Time frame: Baseline to Month 12, Baseline to Month 24
Mean Change From Baseline in Lesion Size
Mean change from baseline in lesion size measured as greatest linear dimension (GLD) of the lesion
Time frame: Baseline to Month 12, Baseline to Month 24
| Milestone | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Started | 39 | 39 | 43 | 41 |
| Completed | 38 | 35 | 37 | 31 |
| Not completed | 1 | 4 | 6 | 10 |
| Withdrew: Adverse event | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 1 |
| Withdrew: Death | 0 | 3 | 2 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 |
Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.
| number of retreatments | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Mean Number of Retreatments (Day 0 Excluded) | 3.97 ± 3.12 | 3.00 ± 2.55 | 4.05 ± 2.93 | 5.39 ± 2.97 |
Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100
| Letters read on ETDRS chart | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart) | 3.6 ± 13.8 | 6.8 ± 13.4 | 5.0 ± 14.2 | 6.5 ± 15.5 |
Retreatment was defined in the protocol as study treatment administered after Day 0. For the analyses of retreatment, any study treatment that was administered was considered to be a retreatment, and combination therapy was considered to be one retreatment, even though two or three treatment procedures were done. In the combination therapy groups, if a ranibizumab injection was given because retreatment was indicated and the previous combination treatment was less than 2 months before, the ranibizumab injection was counted as a retreatment.
| number of retreatments | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Mean Number of Retreatments (Day 0 Excluded) | 5.92 (4.35 to 7.49) | 4.34 (3.09 to 5.60) | 5.92 (4.46 to 7.38) | 8.68 (6.74 to 10.62) |
Early Treatment Diabetic Retinopathy Study (ETDRS) method at 4 meters. Worst = 0; best = 100
| Letters read on ETDRS chart | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Mean Change From Baseline in Study Eye Best-Corrected VA Score | -0.2 (-5.7 to 5.4) | 1.1 (-4.3 to 6.4) | -0.3 (-6.2 to 5.6) | 4.4 (-1.5 to 10.2) |
| Percentage of participants | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Baseline to Month 12 | 25.6 (11.9 to 39.3) | 30.8 (16.3 to 45.3) | 25.6 (12.5 to 38.6) | 24.4 (11.2 to 37.5) |
| Baseline to Month 24 | 20.5 (7.8 to 33.2) | 15.4 (4.1 to 26.7) | 16.3 (5.2 to 27.3) | 26.8 (13.3 to 40.4) |
| Percentage of participants | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Baseline to Month 12 | 64.1 (49.0 to 79.2) | 82.1 (70.0 to 94.1) | 69.8 (56.0 to 83.5) | 70.7 (56.8 to 84.7) |
| Baseline to Month 24 | 61.5 (46.3 to 76.8) | 66.7 (51.9 to 81.5) | 60.5 (45.9 to 75.1) | 70.7 (56.8 to 84.7) |
| Percentage of participants | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Baseline to Month 12 | 12.8 (2.3 to 23.3) | 7.7 (0 to 16.1) | 11.6 (2.0 to 21.2) | 7.3 (0 to 15.3) |
| Baseline to Month 24 | 20.5 (7.8 to 33.2) | 15.4 (4.1 to 26.7) | 20.9 (8.8 to 33.1) | 14.6 (3.8 to 25.5) |
| micron | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Baseline to Month 12 | -115.9 ± 97.4 | -122.2 ± 104.8 | -137.8 ± 122.3 | -100.3 ± 90.1 |
| Baseline to Month 24 | -110.2 ± 93.6 | -123.9 ± 97.1 | -121.0 ± 126.6 | -103.1 ± 99.1 |
Mean change from baseline in lesion size measured as greatest linear dimension (GLD) of the lesion
| micron | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Baseline to Month 12 | 77.2 ± 960.3 | -20.4 ± 1550.7 | 152.0 ± 1415.5 | -192.6 ± 672.5 |
| Baseline to Month 24 | 94.8 ± 865.1 | -103.3 ± 1326.1 | -112.5 ± 1209.4 | -205.3 ± 653.4 |
Collected over Month 0 to Month 24/last visit. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1/4 Fluence Triple Therapy | — | 10/39 (25.6%) | 36/39 (92.3%) |
| 1/2 Fluence Triple Therapy | — | 13/39 (33.3%) | 36/39 (92.3%) |
| 1/2 Fluence Double Therapy | — | 15/43 (34.9%) | 36/43 (83.7%) |
| Ranibizumab | — | 19/41 (46.3%) | 37/41 (90.2%) |
| Event | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/39 | 3/39 | 0/43 | 3/41 |
| Congestive Heart FailureCardiac disorders | 0/39 | 2/39 | 1/43 | 3/41 |
| HypertensionCardiac disorders | 0/39 | 0/39 | 0/43 | 3/41 |
| Accidental InjuryGeneral disorders | 0/39 | 2/39 | 1/43 | 1/41 |
| Acute kidney failureRenal and urinary disorders | 0/39 | 2/39 | 0/43 | 2/41 |
| Angina pectorisCardiac disorders | 0/39 | 2/39 | 1/43 | 0/41 |
| SepsisGeneral disorders | 0/39 | 2/39 | 0/43 | 0/41 |
| SyncopeCardiac disorders | 0/39 | 2/39 | 0/43 | 1/41 |
| Atrial fibrillationCardiac disorders | 0/39 | 1/39 | 1/43 | 2/41 |
| Breast carcinomaReproductive system and breast disorders | 0/39 | 1/39 | 0/43 | 2/41 |
| Event | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab |
|---|---|---|---|---|
| Chest painGeneral disorders | 2/39 | 1/39 | 2/43 | 1/1 |
| Eye pain (study eye)Eye disorders | 7/39 | 9/39 | 9/43 | 10/41 |
| Accidental InjuryGeneral disorders | 6/39 | 5/39 | 7/43 | 9/41 |
| Age-related Macular Degeneration progression (fellow eye)Eye disorders | 3/39 | 8/39 | 1/43 | 2/41 |
| Vision abnormal (study eye)Eye disorders | 8/39 | 1/39 | 7/43 | 4/41 |
| InfectionGeneral disorders | 7/39 | 7/39 | 5/43 | 8/41 |
| HypertensionCardiac disorders | 7/39 | 2/39 | 7/43 | 5/41 |
| Increased intraocular pressure (study eye)Eye disorders | 4/39 | 4/39 | 6/43 | 6/41 |
| Urinary tract infectionRenal and urinary disorders | 2/39 | 3/39 | 4/43 | 6/41 |
| Cataract (study eye)Eye disorders | 2/39 | 4/39 | 6/43 | 1/41 |
| Age Continuous(years) | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab | Total |
|---|---|---|---|---|---|
| Mean | 78 ± 8 | 78 ± 8 | 79 ± 6 | 79 ± 5 | 79 ± 7 |
| Sex: Female, Male(Participants) | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab | Total |
|---|---|---|---|---|---|
| Female | 20 | 24 | 23 | 28 | 95 |
| Male | 19 | 15 | 20 | 13 | 67 |
| Lesion composition(participants) | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab | Total |
|---|---|---|---|---|---|
| Minimally classic | 6 | 4 | 9 | 8 | 27 |
| Occult no classic | 10 | 16 | 20 | 18 | 64 |
| Predominantly classic | 23 | 19 | 14 | 15 | 71 |
| Central retinal thickness(micron) | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab | Total |
|---|---|---|---|---|---|
| Mean | 318.3 ± 95.9 | 337.3 ± 106.8 | 337.3 ± 121.4 | 311.9 ± 95.5 | 326.3 ± 105.4 |
| Lesion size (greatest linear dimension)(micron) | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab | Total |
|---|---|---|---|---|---|
| Mean | 2778.8 ± 1025.6 | 2740.1 ± 846.1 | 2796.1 ± 1122.8 | 3118.4 ± 1155.7 | 2860.1 ± 1049.4 |
| Study Eye Best-corrected Visual Acuity Score (ETDRS chart)(Letters read on ETDRS chart) | 1/4 Fluence Triple Therapy | 1/2 Fluence Triple Therapy | 1/2 Fluence Double Therapy | Ranibizumab | Total |
|---|---|---|---|---|---|
| Mean | 58.1 ± 11.8 | 55.6 ± 11.2 | 53.3 ± 11.9 | 56.0 ± 13.1 | 55.7 ± 12.0 |
The record gives a start of Jul 2007, a primary completion of May 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →
QLT Inc.